NCT02009956

EXCELLA Post-Approval Study

POST MARKETING STUDY OF THE ELIXIR DESyne® NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne® BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Elixir Medical Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate long-term safety and performance of the DESyne Novolimus Eluting Coronary Stent System and the DESyne BD Novolimus Eluting Coronary Stent System

Detailed description

DESyne and DESyne BD are not currently approved for sale in the United States.

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DEVICE	Subjects receiving DESyne Novolimus Eluting CSS

Timeline

• Start date: 2014-02-26
• Primary completion: 2015-03-02
• Completion: 2016-06-01
• First posted: 2013-12-12
• Last updated: 2021-04-26

Locations

4 sites across 3 countries: Germany, Jordan, Spain